TOKYO, Mar 23 (Pulse News Wire) – Oncolys BioPharma Inc. (4588.T) announced today that its OBP-601 (generic name: censavudine) has secured a patent application for treating neurodegenerative diseases caused primarily by LINE-1 transposition in Europe.
The patent was filed by Brown University and licensed out to Transposon Inc. This marks the completion of patent registrations in Japan, the United States, Europe, and China for this particular use case.
With this patent, Transposon plans to initiate new clinical trials targeting progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS), and Alzheimer's disease, leveraging OBP-601’s novel mechanism of LINE-1 inhibition. As a result of this patent, Transposon will hold exclusive rights until 2040 for any of the aforementioned conditions covered by the clinical trials.
The company stated that there would be no impact on its fiscal year ending December 2026 performance due to this patent acquisition.
🟢 Confidence: High AI-translated content.